International Tech Times
SEE OTHER BRANDS

Your science and technology news reporter

International Tech Times: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on International Tech Times.

Press releases published on April 14, 2025

Certara Reports Preliminary First Quarter 2025 Financial Results; Announces $100 Million Share Repurchase Authorization

Certara Reports Preliminary First Quarter 2025 Financial Results; Announces $100 Million Share Repurchase Authorization

Reiterates Full-Year 2025 Guidance Arsenal Capital Partners agrees to a one-year lock-up RADNOR, Pa., April 14, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced expected revenue and …

Western Uranium & Vanadium Corp. Announces Ore Purchase Agreement

Western Uranium & Vanadium Corp. Announces Ore Purchase Agreement

Toronto, Ontario and Nucla, Colorado, April 14, 2025 (GLOBE NEWSWIRE) -- Western Uranium …

Bitcoin 2.0: BloomBeans Offers $150M Airdrop for a New Economic Foundation

Bitcoin 2.0: BloomBeans Offers $150M Airdrop for a New Economic Foundation

Lisbon, Portugal, April 14, 2025 (GLOBE NEWSWIRE) -- BloomBeans.io is releasing the first decentraliced financial system to substitute Bitcoin. A New Global Financial System Lead by Takashi Nakamoto and designed by Austrian economists, BloomBeans operates …

NowVertical to Present at the Planet MicroCap Showcase: VEGAS in partnership with MicroCapClub on Wednesday, April 23, 2025

NowVertical to Present at the Planet MicroCap Showcase: VEGAS in partnership with MicroCapClub on Wednesday, April 23, 2025

TORONTO, April 14, 2025 (GLOBE NEWSWIRE) -- NowVertical Group Inc. (TSXV: NOW) ("NowVertical" or the "Company"), a leading data and AI solutions provider, today announced that it will be presenting at the Planet MicroCap Showcase: VEGAS 2025 in partnership …

Volatus Aerospace Obtient une Prolongation de son Entente de Services avec le Gouvernement du Canada

Volatus Aerospace Obtient une Prolongation de son Entente de Services avec le Gouvernement du Canada

MONTRÉAL, 14 avr. 2025 (GLOBE NEWSWIRE) -- Volatus Aerospace Inc. (TSXV : FLT) (OTCQX : TAKOF) (Francfort : A2JEQU) (« Volatus » ou la « Société »), chef de file en solutions aériennes, annonce fièrement la prolongation d’un an, soit la durée maximale …

Volatus Aerospace Secures Extension to Service Agreement with Canadian Government

Volatus Aerospace Secures Extension to Service Agreement with Canadian Government

MONTREAL, April 14, 2025 (GLOBE NEWSWIRE) -- Volatus Aerospace Inc. (TSXV: FLT) (OTCQX: TAKOF) (Frankfurt: A2JEQU) ("Volatus" or "the Company"), a leader in aerial solutions, proudly announces a one-year extension, the maximum allowable, to its Public …

Swarm Joins Hivello—Marking the 10th DePIN Network Aggregated

Swarm Joins Hivello—Marking the 10th DePIN Network Aggregated

LONDON and AMSTERDAM, April 14, 2025 (GLOBE NEWSWIRE) -- Hivello, a DePIN aggregator that enables users to earn by monetizing idle computer resources across multiple DePINs (Decentralized Physical Infrastructure Networks), has officially integrated Swarm …

Qorvo® Announces Results of Board Refreshment Process

Qorvo® Announces Results of Board Refreshment Process

Appoints Richard L. Clemmer and Christopher R. Koopmans as Independent Directors David H. Y. Ho to Retire from the Board GREENSBORO, N.C., April 14, 2025 (GLOBE NEWSWIRE) -- Qorvo® (Nasdaq:QRVO), a leading global provider of connectivity and power …

Relmada Therapeutics To Present NDV-01 Data at AUA2025

Relmada Therapeutics To Present NDV-01 Data at AUA2025

CORAL GABLES, Fla., April 14, 2025 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada”, “the Company”), a clinical-stage biotechnology company, today announced the presentation of an abstract at the American Urology Association (AUA2025 …

Dragonfly Energy’s Battle Born® Mobile App Now Available for Android Users

Dragonfly Energy’s Battle Born® Mobile App Now Available for Android Users

RENO, Nev., April 14, 2025 (GLOBE NEWSWIRE) -- Android users can now wirelessly monitor and manage their Battle Born® smart battery systems through the newly released Battle Born Mobile App, available on the Google Play Store. Developed by Dragonfly Energy …

American Tungsten Corp. Announces New CEO, Ali Haji

American Tungsten Corp. Announces New CEO, Ali Haji

Vancouver, BC, April 14, 2025 (GLOBE NEWSWIRE) -- American Tungsten Corp. (CSE:TUNG) (OTCQB:DEMRF) (FSE:RK9) (“American Tungsten” or the “Company”) today announces that Ali Haji has been appointed as Chief Executive Officer. Murray Nye will assume the role …

XOMA Royalty Completes Sale of Kinnate Pipeline Assets

XOMA Royalty Completes Sale of Kinnate Pipeline Assets

XOMA Royalty sold the remaining Kinnate pipeline assets for a total of up to $270 million in upfront and milestone payments, plus royalties on commercial sales at rates ranging from low single digits to mid-teens Holders of Kinnate Contingent Value Rights …

Avicanna Reports Full Year 2024 Audited Financial Statement

Avicanna Reports Full Year 2024 Audited Financial Statement

2024 Revenue of $25.5M, a 52% increase from 2023 Consolidated Gross Margins of 51%, Gross Profits of $12.9M, a 94% increase from 2023 TORONTO, April 14, 2025 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company) (TSX: AVCN) (OTCQX: AVCNF) (FSE: …

SynOx Therapeutics Receives Fast Track Designation from U.S. Food and Drug Administration for Emactuzumab for Tenosynovial Giant Cell Tumours (TGCT)

SynOx Therapeutics Receives Fast Track Designation from U.S. Food and Drug Administration for Emactuzumab for Tenosynovial Giant Cell Tumours (TGCT)

DUBLIN, Ireland and OXFORD, United Kingdom, April 14, 2025 (GLOBE NEWSWIRE) -- SynOx Therapeutics Limited (“SynOx”), a late-stage clinical biopharmaceutical company developing of emactuzumab for Tenosynovial Giant Cell Tumours (TGCT), today announced that …

Lifecore Biomedical Appoints Thomas D. Salus as Chief Legal and Administration Officer

Lifecore Biomedical Appoints Thomas D. Salus as Chief Legal and Administration Officer

Mr. Salus Brings More than 30 Years of Broad-Based Legal and Management Expertise Highlighted by Extensive Experience within Life Sciences Industry Significantly Elevates Lifecore’s Capabilities Across Corporate Governance, Transactional Activities, and …

ProQR Strengthens Leadership with Appointments of CFO and CMO to Support Next Phase of Growth

ProQR Strengthens Leadership with Appointments of CFO and CMO to Support Next Phase of Growth

LEIDEN, Netherlands …

Soleno Therapeutics Announces VYKAT(TM) XR Launch

Soleno Therapeutics Announces VYKAT(TM) XR Launch

REDWOOD CITY, Calif., April 14, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced the U.S. commercial availability of …

10 Barrel Brewing Co. and Scout Campers Unveil Camp Coldie: The Ultimate Adventure Beer

10 Barrel Brewing Co. and Scout Campers Unveil Camp Coldie: The Ultimate Adventure Beer

BEND, Ore., April 14, 2025 (GLOBE NEWSWIRE) -- 10 Barrel Brewing, a Tilray Brands, Inc., craft beer brand (NASDAQ: TLRY and TSX: TLRY), introduces Camp Coldie, 10 Barrel Brewing Co.’s highly-crushable new 5% IPA brewed in partnership with Scout Campers. …

Aya Gold & Silver Announces Appointment of John Burzynski to the Board and Departure of Nikolaos Sofronis

Aya Gold & Silver Announces Appointment of John Burzynski to the Board and Departure of Nikolaos Sofronis

MONTREAL, April 14, 2025 (GLOBE NEWSWIRE) -- Aya Gold & Silver Inc. (TSX: AYA; OTCQX: AYASF) (“Aya” or the “Corporation”) is pleased to announce the appointment of Mr. John Burzynski to its Board of Directors as an Independent Director, effective …

Verve Therapeutics Announces Positive Initial Data from the Heart-2 Phase 1b Clinical Trial of VERVE-102, an In Vivo Base Editing Medicine Targeting PCSK9

Verve Therapeutics Announces Positive Initial Data from the Heart-2 Phase 1b Clinical Trial of VERVE-102, an In Vivo Base Editing Medicine Targeting PCSK9

Single infusion of VERVE-102 led to dose-dependent decreases in blood PCSK9 and LDL-C, with mean reduction in LDL-C of 53% and a maximum reduction of 69% observed in the 0.6 mg/kg dose cohort VERVE-102 was well-tolerated with no treatment-related serious …

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms of Service